Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth

Core Insights - Kamada Ltd. reported strong financial results for the third quarter and the first nine months of 2025, with total revenues of $135.8 million, an 11% year-over-year increase, and adjusted EBITDA of $34.2 million, up 35% year-over-year [2][6][11]. Financial Performance - Third quarter revenues reached $47.0 million, a 13% increase from $41.7 million in the same quarter of 2024 [6][7]. - Gross profit for the third quarter was $19.8 million, with a gross margin of 42%, compared to $17.2 million and 41% in the prior year [7]. - For the first nine months of 2025, gross profit was $59.4 million, with a gross margin of 44%, up from $52.9 million and 43% in the same period of 2024 [11][12]. - Net income for the first nine months was $16.6 million, or $0.29 per diluted share, a 56% increase from $10.7 million, or $0.18 per diluted share, in the same period of 2024 [11][12]. Operational Highlights - The company generated $17.9 million in cash from operating activities during the first nine months of 2025, contributing to a cash position of $72.0 million as of September 30, 2025 [2][9]. - Kamada continues to invest in plasma collection operations, recently receiving FDA approval for its Houston facility, which is expected to be one of the largest collection centers for specialty plasma in the U.S. [4][12]. - The company is advancing its pivotal Phase 3 InnovAATe clinical trial for inhaled Alpha-1 Antitrypsin therapy, with an interim futility analysis expected by the end of 2025 [4][11]. Strategic Initiatives - Kamada is focused on expanding its product portfolio and securing long-term sales agreements for normal source plasma [4][12]. - The company has launched a comprehensive post-marketing research program for CYTOGAM® to support its benefits in managing cytomegalovirus (CMV) in solid organ transplantation [3][12]. - The company reiterated its full-year 2025 revenue guidance of $178 million to $182 million and adjusted EBITDA guidance of $40 million to $44 million, indicating a positive outlook for the remainder of the year [2][11].